Primacy of resistance rather than toxicity in determining outcome of therapy for AML

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue , 2014, Pages S56-S58

  Estey, Elihu H ^a,b,c  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

3+7; Induction therapy; Older patients; Therapeutic resistance; Treatment related mortality

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; CYTARABINE; CYTARABINE PLUS DAUNORUBICIN; DAUNORUBICIN; DECITABINE; IDARUBICIN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACUTE MYELOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER SURVIVOR; CONFERENCE PAPER; DRUG EFFICACY; DRUG TREATMENT FAILURE; GROUPS BY AGE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; SURVIVAL RATE; TREATMENT RELATED MORTALITY; DRUG RESISTANCE; LEUKEMIA, MYELOID, ACUTE; MORTALITY; REMISSION; RISK FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, ACUTE; REMISSION INDUCTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 84939424887     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.04.016     Document Type: Conference Paper

References (9)

1. E. Feldman, J. Lancet, J. Kolitz, and et al. First in many study of CPX 35, a liposomal carrie containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia J Clin Oncol 29 2011 979 985
2. J. Orozco, T. Back, A. Kenoyer, and et al. Anti-CD45 radioimmunotherapy using (211) At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model Blood 121 2013 3759 3767
3. R.B. Walter, M. Othus, G. Borthakur, and et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment J Clin Oncol 29 2011 4417 4423
4. F.R. Appelbaum, H. Gundacker, D.R. Head, and et al. Age and acute myeloid leukemia Blood 107 2006 3481 3485
5. J. Menzin, K. Lang, C.C. Earle, D. Kerney, and R. Mallick The outcomes and costs of acute myeloid leukemia among the elderly Arch Intern Med 162 2002 1597 1603
6. M. Yanada, G. Garcia-Manero, G. Borthakur, F. Ravandi, H. Kantarjian, and E. Estey Relapse and death during first remission in acute myeloid leukemia Haematologica 93 2008 633 634
7. J. Cornelissen, A. Gratwohl, R. Schlenk, and et al. The Europe LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach Nat Rev Clin Oncol 9 2012 579 590
8. T.A. Gooley, J.W. Chien, S.A. Pergam, and et al. Reduced mortality after allogeneic hematopoietic cell transplantation N Engl J Med 363 2010 2091 2210
9. M. Othus, H. Kantarjian, S. Petersdorf, and et al. Declining rates of treatment-related mortality in patients with newly diagnosed acute myeloid leukemia given "intensive" induction regimens: a report from SWOG and M.D. Anderson Leukemia 28 2014 289 292